|Table of Contents|

Predictive value of dynamic changes of NLR and PLR on the efficacy and prognosis of patients with advanced non-small cell lung cancer receiving anti PD-1/PD-L1 treatment

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 12
Page:
2247-2254
Research Field:
Publishing date:

Info

Title:
Predictive value of dynamic changes of NLR and PLR on the efficacy and prognosis of patients with advanced non-small cell lung cancer receiving anti PD-1/PD-L1 treatment
Author(s):
TANG Gaoyan; LIU Yan; ZHANG Qingyun; LI Na; YU Guohua
Department of Oncology,Weifang People's Hospital,Shandong Weifang 261041,China.
Keywords:
NLR; PLR; NSCLC; immunotherapy; prognosis
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.12.013
Abstract:
Objective:To investigate the usefulness of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at baseline and 12 weeks after treatment and their dynamic changes for immuneresponse in advanced non-small-cell lung cancer(aNSCLC) patients.Methods:We retrospectively analyzed 60 patients with aNSCLC who received immunotherapy in our hospital from January 2018 to May 2019.The NLR and PLR were assessed at baseline (NLR0 and PLR0) and 12 weeks after treatment(NLR12 and PLR12).Changes in NLR and PLR were obtained by subtracting the initial value from the value obtained at 12 weeks after treatment.Results:In all aNSCLC patients on immunotherapy,47(78.3%) cases were in the response group.Whether at baseline or 12 weeks after treatment,the levels of NLR and PLR in the response group were both significantly lower than those in the non-response group (P<0.05).Patients with a high NLR12 had poor progression-free survival (PFS) and overall survival (OS) independently in multivariate analysis.Patients with high NLR0-high NLR12 were associated with poor PFS and OS(P=0.009,P=0.001 respectively).Results were similar for PLR.Conclusion:NLR at 12 weeks after treatment appears to be a more accurate biomarker than NLR at baseline.In addition,considering dynamic changes of NLR and PLR during immunotherapy might help to predict a more accurate prognosis in aNSCLC patients.

References:

［1］REN S,CHEN J,XU X,et al.Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC(CameL-Sq):A phase 3 trial［J］.Journal of Thoracic Oncology,2022,17(4):544-557.
［2］BORGHAEI H,CIULEANU TE,LEE JS,et al.Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer:a pooled analysis［J］.Annals of Oncology,2023,34(2):173-185.
［3］BRAHMER J,RECKAMP KL,BAAS P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer［J］.The New England Journal of Medicine,2015,373(2):123-135.
［4］BORGHAEI H,PAZ-ARES L,HORN L,et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer［J］.The New England Journal of Medicine,2015,373(17):1627-1639.
［5］HERBST RS,BAAS P,KIM DW,et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial［J］.Lancet (London,England),2016,387(10027):1540-1550.
［6］GARON EB,RIZVI NA,HUI R,et al.Pembrolizumab for the treatment of non-small-cell lung cancer［J］.The New England Journal of Medicine,2015,372(21):2018-2028.
［7］FERRARA R,MEZQUITA L,TEXIER M,et al.Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy［J］.JAMA Oncology,2018,4(11):1543-1552.
［8］COSTANTINI A,FALLET V,CORNY J,et al.Nivolumab-refractory patients with advanced non-small-cell lung cancer［J］.Lung Cancer(Amsterdam,Netherlands),2019,130:128-134.
［9］ZHAO J,WU Y,YUE Y,et al.The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer［J］.Thoracic Cancer,2023,14(5):497-505.
［10］LIU J,AO W,ZHOU J,et al.The correlation between PLR-NLR and prognosis in acute myocardial infarction［J］.American Journal of Translational Research,2021,13(5):4892-4899.
［11］MIYAMOTO R,INAGAWA S,SANO N,et al.The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients［J］.European Journal of Surgical Oncology,2018,44(5):607-612.
［12］ZHANG J,ZHANG HY,LI J,et al.The elevated NLR,PLR and PLT may predict the prognosis of patients with colorectal cancer:a systematic review and meta-analysis［J］.Oncotarget,2017,8(40):68837-68846.
［13］NAKAYA A,KURATA T,YOSHIOKA H,et al.Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab［J］.International Journal of Clinical Oncology,2018,23(4):634-640.
［14］PINATO DJ,SHINER RJ,SECKL MJ,et al.Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer［J］.British Journal of Cancer,2014,110(8):1930-1935.
［15］ZHANG H,XIA H,ZHANG L,et al.Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer［J］.American Journal of Surgery,2015,210(3):526-535.
［16］CHENG H,BHUSHAN S,LI N,et al.Preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are correlated with tumor-node-metastasis stages in patients with non-small cell lung cancer［J］.Journal of Cancer Research and Therapeutics,2022,18(6):1666-1673.
［17］GU X,SUN S,GAO XS,et al.Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer:evidence from 3,430 patients［J］.Scientific Reports,2016,6:23893.
［18］PLATINI H,FERDINAND E,KOHAR K,et al.Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers for advanced non-small-cell lung cancer treated with immunotherapy:a systematic review and Meta-analysis［J］.Medicina(Kaunas,Lithuania),2022,58(8):1069.
［19］WU W,WANG X,LE W,et al.Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer［J］.Frontiers in immunology,2022,13:1001297.
［20］CRAINICIUC G,PALOMINO-SEGURA M,MOLINA-MORENO M,et al.Behavioural immune landscapes of inflammation［J］.Nature,2022,601(7893):415-421.
［21］TAMURA K,MIYATO H,KANAMARU R,et al.Activated neutrophils inhibit chemotactic migration of activated T lymphocytes to CXCL11 by multiple mechanisms［J］.Cellular Immunology,2023,384:104663.
［22］BYUN SS,HWANG EC,KANG SH,et al.Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in nonmetastatic renal cell carcinoma:A large,multicenter cohort analysis［J］.BioMed Research International,2016,2016:5634148.
［23］WANG SC,CHOU JF,STRONG VE,et al.Pretreatment neutrophil to lymphocyte ratio independently predicts disease-specific survival in resectable gastroesophageal junction and gastric adenocarcinoma［J］.Annals of Surgery,2016,263(2):292-297.
［24］GRENADER T,WADDELL T,PECKITT C,et al.Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer:exploratory analysis of the REAL-2 trial［J］.Annals of Oncology,2016,27(4):687-692.
［25］TAKAHASHI Y,KAWAMURA M,HATO T,et al.Neutrophil-lymphocyte ratio as a prognostic marker for lung adenocarcinoma after complete resection［J］.World Journal of Surgery,2016,40(2):365-372.
［26］KUMAR A,WATKINS R,VILGELM AE.Cell therapy with TILs:Training and taming T cells to fight cancer［J］.Frontiers in Immunology,2021,12:690499.
［27］OH SY,KIM YB,SUH KW.Prognostic significance of systemic inflammatory response in stage II colorectal cancer［J］.The Journal of Surgical Research,2017,208:158-165.
［28］BATES M,MOHAMED BM,WARD MP,et al.Circulating tumour cells:The good,the bad and the ugly［J］.Biochimica et Biophysica Acta Reviews on Cancer,2023,1878(2):188863.
［29］DAI L,LIANG BM,OU XM.Predictive value of neutrophil-to-lymphocyte ratio and bilirubin levels in the readmission of acute exacerbation of chronic obstructive pulmonary disease［J］.The American Journal of the Medical Sciences,2023,365(2):169-175.
［30］KARATAS M,GUNDUZOZ M,OZIST N,et al.Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as haematological indices of inflammatory response in ceramic workers' silicosis［J］.The Clinical Respiratory Journal,2019,13(3):159-165.
［31］CUMMINGS M,MERONE L,KEEBLE C,et al.Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival［J］.British Journal of Cancer,2015,113(2):311-320.
［32］MANDALIYA H,JONES M,OLDMEADOW C,et al.Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC):neutrophil to lymphocyte ratio (NLR),lymphocyte to monocyte ratio (LMR),platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)［J］.Translational Lung Cancer Research,2019,8(6):886-894.
［33］MANO R,FLYNN J,BLUM KA,et al.The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma［J］.Urologic Oncology,2019,37(12):916-923.
［34］DIEM S,SCHMID S,KRAPF M,et al.Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab［J］.Lung Cancer (Amsterdam,Netherlands),2017,111:176-181.
［35］SUH KJ,KIM SH,KIM YJ,et al.Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody［J］.Cancer Immunology,Immunotherapy:CII,2018,67(3):459-470.
［36］CHEN Y,WEN S,XIA J,et al.Association of dynamic changes in peripheral blood indexes with response to PD-1 inhibitor-based combination therapy and survival among patients with advanced non-small cell lung cancer［J］.Frontiers in Immunology,2021,12:672271.
［37］LIN JX,WANG ZK,HUANG YQ,et al.Dynamic changes in pre-and postoperative levels of inflammatory markers and their effects on the prognosis of patients with gastric cancer［J］.Journal of Gastrointestinal Surgery,2021,25(2):387-396.
［38］KIM JY,JUNG EJ,KIM JM,et al.Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis［J］.BMC Cancer,2020,20(1):1206.
［39］MASON M,MAURICE C,MCNAMARA MG,et al.Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival［J］.Journal of Neuro-oncology,2017,132(3):463-471.

Memo

Memo:
潍坊市卫生健康委员会科研基金资助项目（编号：WFWSJK-2022-109)
Last Update: 1900-01-01